Skip to main content
HairCited

두타스테리드 관련 안드로겐성 탈모

A

총 12,060명의 참여자를 대상으로 한 43건의 연구(메타분석 7건, RCT 1건)에 근거합니다. 43건 중 34건의 연구에서 긍정적인 효과가 나타났습니다.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Ddutasteride\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

결론

Dutasteride has strong scientific support for androgenetic alopecia and research suggests it may be more effective than finasteride, though it should be used under medical supervision due to potential side effects.

  • 34 out of 43 studies show positive effects across 12,060 participants
  • Multiple meta-analyses consistently support dutasteride's effectiveness for pattern hair loss
  • Blocks both type I and type II 5-alpha reductase enzymes, potentially offering broader DHT reduction than finasteride
  • Available in both oral and topical formulations, with topical forms being actively researched

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None 효과: None None

대상 집단: women with androgenetic alopecia (female pattern hair loss)

Randomized Controlled Trial n=139 24 weeks Double-blind
Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, …
Dose: 0.2 mg dutasteride daily vs: Placebo; 0.5 mg dutasteride daily Outcome: Change in hair count at vertex from baseline 효과: 21.53 vs 5.96 hair count increase 0.0072

대상 집단: Men with androgenetic alopecia

Controlled Clinical Trial n=8 12 weeks Single-blind
Dutasteride Infusion in Male Androgenetic Alopecia Using a Novel Drug Delivery Technique: MMP®.
Dose: 3 sessions of dutasteride microinfusion (monthly) vs: Saline solution placebo via MMP Outcome: Clinical assessment and patient self-assessment 효과: None None

대상 집단: Adult males with androgenetic alopecia

Other n=20 8 weeks Open-label
Efficacy of Skin Patting and Iontophoresis with Dutasteride Gel in Male and Menopausal Female Androgenetic …
Dose: 4 monthly sessions of SPi + iontophoresis vs: Baseline (pre-post design, no control) Outcome: Hair density, shaft diameter, pull test at 8 … 효과: None <0.001 (density, diam, pull)

대상 집단: 10 males + 10 postmenopausal females with resistant AGA

Review
Efficacy and safety of dutasteride in the treatment of alopecia: a comprehensive review.
Dose: Dutasteride (oral, various doses) vs: Placebo 효과: None None
Review
Male and female pattern hair loss.
Dose: None vs: Placebo 효과: None None

Key Statistics

99

연구

19921

참여자

Positive

A

등급

Referenced Papers

Journal of cosmetic … 2025 3 인용
Australian prescriber 2025 2 인용
Journal of clinical … 2025 1 인용
Annals of dermatology 2025
Dermatology (Basel, Switzerland) 2024 14 인용
Journal of cosmetic … 2024 11 인용
Facial plastic surgery … 2024 8 인용
American journal of … 2023 41 인용
Fertility and sterility 2020 94 인용
Neurobiology of stress 2020 72 인용
Facial plastic surgery … 2020 15 인용
Alternative therapies in … 2020 11 인용
The aging male … 2019 19 인용
Assay and drug … 2019 19 인용
Expert opinion on … 2018 38 인용
Current clinical pharmacology 2017 62 인용
International journal of … 2017 45 인용
Actas dermo-sifiliograficas 2017 17 인용
The Cochrane database … 2016 18 인용
Indian journal of … 2016 8 인용
Current problems in … 2015 8 인용
Expert opinion on … 2014 57 인용
Current opinion in … 2014 43 인용
Dermatologic clinics 2013 78 인용
Journal of cosmetic … 2013 62 인용
Facial plastic surgery … 2013 16 인용
International journal of … 2013
Expert opinion on … 2010 264 인용
Current opinion in … 2009 54 인용
Seminars in cutaneous … 2009 4 인용

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

hairloss:
0.5 mg/day (off-label)

상한량: 0.5 mg/day

연구에서 사용된 용량

용량 기간 효과 N
None -- Neutral --
0.2 mg dutasteride daily 24 weeks Positive 139
3 sessions of dutasteride microinfusion (monthly) 12 weeks Positive 8
4 monthly sessions of SPi + iontophoresis 8 weeks Positive 20
Dutasteride (oral, various doses) -- Positive --
None -- Positive --
None -- Positive --
None -- Positive --

권장 복용 시간: Once daily at the same time, with or without food; prescription required

Safety & Side Effects

보고된 부작용

  • Decreased libido (more common than finasteride)
  • Erectile dysfunction
  • Ejaculation disorders
  • Gynecomastia (breast tissue growth)
  • Very long half-life (~5 weeks) means slow side effect resolution

알려진 상호작용

  • CYP3A4 inhibitors (ketoconazole, ritonavir) may increase dutasteride levels
  • May affect PSA levels (reduces by ~50%)
  • Contraindicated in pregnancy (Category X teratogen)

일일 최대 섭취 허용량: 0.5 mg/day

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does 두타스테리드 help with 안드로겐성 탈모?
Based on 99 studies with 19,921 participants, there is strong evidence from multiple clinical trials that 두타스테리드 may support 안드로겐성 탈모 management. Our evidence grade is A (Strong Evidence).
How much 두타스테리드 should I take for 안드로겐성 탈모?
Studies have used various dosages. A commonly studied range is 0.5 mg/day (off-label). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 두타스테리드?
Reported side effects may include Decreased libido (more common than finasteride), Erectile dysfunction, Ejaculation disorders, Gynecomastia (breast tissue growth). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 두타스테리드 and 안드로겐성 탈모?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 99 peer-reviewed studies with 19,921 total participants. The overall direction of effect is positive.

Related Evidence

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.